| Literature DB >> 28394477 |
Kenta Arai1, Toshiki Takei1,2, Masaki Okumura3, Satoshi Watanabe3, Yuta Amagai3, Yuya Asahina2, Luis Moroder4, Hironobu Hojo2, Kenji Inaba3, Michio Iwaoka1.
Abstract
Synthetic insulin analogues with a long lifetime are current drug targets for the therapy of diabetic patients. The replacement of the interchain disulfide with a diselenide bridge, which is more resistant to reduction and internal bond rotation, can enhance the lifetime of insulin in the presence of the insulin-degrading enzyme (IDE) without impairing the hormonal function. The [C7UA ,C7UB ] variant of bovine pancreatic insulin (BPIns) was successfully prepared by using two selenocysteine peptides (i.e., the C7U analogues of A- and B-chains, respectively). In a buffer solution at pH 10 they spontaneously assembled under thermodynamic control to the correct insulin fold. The selenoinsulin (Se-Ins) exhibited a bioactivity comparable to that of BPIns. Interestingly, degradation of Se-Ins with IDE was significantly decelerated (τ1/2 ≈8 h vs. ≈1 h for BPIns). The lifetime enhancement could be due to both the intrinsic stability of the diselenide bond and local conformational changes induced by the substitution.Entities:
Keywords: amino acids; drug discovery; protein folding; selenium; structure elucidation
Mesh:
Substances:
Year: 2017 PMID: 28394477 DOI: 10.1002/anie.201701654
Source DB: PubMed Journal: Angew Chem Int Ed Engl ISSN: 1433-7851 Impact factor: 15.336